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ABSTRACT
Introduction: Risankizumab has demonstrated
efficacy in treating moderate-to-severe psoriasis.
The phase-3 IMMhance trial (NCT02672852)
examined the effect of continuing versus with-
drawing from risankizumab treatment on pso-
riasis severity, including the Psoriasis Area and
Severity Index (PASI) and static Physician Glo-
bal Assessment (sPGA). However, the effect of
withdrawal on health-related quality of life
(HRQL) was not assessed. Therefore, this study
was conducted to evaluate the impact of risan-
kizumab withdrawal on HRQL measured by the
Dermatology Life Quality Index (DLQI).
Because DLQI was not measured beyond week
16 in IMMhance, a machine learning predictive
model for DLQI was developed.
Methods: A machine learning model for DLQI
was fitted using repeated measures data from
three phase-3 trials (NCT02684370,
NCT02684357, NCT02694523) (pooled
N = 1602). An elastic-net algorithm performed
automated variable selection among candidate
predictors including concurrent PASI and sPGA,
demographics, and interaction terms. The
machine learning model was used to predict
DLQI at weeks 28–104 of IMMhance among
patients re-randomized to continue (N = 111) or
withdraw from (N = 225) risankizumab after
achieving response (sPGA = 0/1) at week 28.
Results: The machine learning predictive
model demonstrated good statistical fit during
tenfold cross-validation and external validation
against observed DLQI at weeks 0–16 of
IMMhance (N = 507). Predicted improvements
in DLQI from baseline were lower in the with-
drawal versus the continuation cohort (mean
DLQI change at week 104, -5.9 versus -11.5,
difference [95% CI] = 5.6 [4.1, 7.3]). Predicted
DLQI deteriorated more extensively than PASI
(49.7% versus 36.4%) after treatment
withdrawal.
Conclusions: The predicted DLQI score deteri-
orated more rapidly after risankizumab with-
drawal than the PASI score, an objective
measure of disease. These findings suggest that
the deterioration in HRQL reflects more sub-
stantial impacts after risankizumab
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Key Summary Points
Why carry out this study?
Although the efficacy of risankizumab in
the treatment of moderate-to-severe
psoriasis has been demonstrated in a
recent phase 3 clinical trial, the impact of
its withdrawal on patients’ health-related
quality of life (HRQL) has not yet been
assessed.
This study was conducted to gain insight
regarding the impact of risankizumab
withdrawal on HRQL among patients with
moderate-to-severe psoriasis from
IMMhance using the Dermatology Life
Quality Index (DLQI); however, due to the
absence of DLQI collected beyond week
16 in clinical trials, a machine learning
predictive model was developed to assess
the DLQI among patients with moderate-
to-severe psoriasis.
What was learned from the study?
The DLQI scores calculated using the
machine learning predictive model
showed that patients who withdrew from
risankizumab experienced more extensive
deterioration in their HRQL compared
with patients who continuously remained
on treatment.
When compared with the Psoriasis Area
and Severity Index (PASI), a commonly
used objective measure of clinical severity,
the DLQI score showed a larger relative
decline, suggesting that this measure of
HRQL is affected by risankizumab
withdrawal more extensively than clinical
measures would suggest.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article, go to https://doi.org/10.6084/
m9.figshare.14541864.
INTRODUCTION
Plaque psoriasis is a chronic inflammatory skin
condition, characterized by pruritic and scaly
lesions (plaques) throughout the patient’s body
[1]. Patients with plaque psoriasis experience
debilitating pain, stigmatization [2], and psy-
chosocial impairments [3, 4] due to the
appearance of lesions, and are susceptible to
multiple comorbidities (e.g., metabolic syn-
drome, cardiovascular disease) [5]. This has
resulted in a substantial decrease in patients’
health-related quality of life (HRQL) [6–9],
which typically correlates with disease severity
(e.g., mild, moderate, severe) [5].
Although there is no cure for psoriasis,
treatments are available to assist in providing
sustained clearance of lesions, particularly
among patients with moderate-to-severe plaque
psoriasis [10]. Several clinician-reported out-
come measures are used to evaluate the mag-
nitude of the disease burden and the
effectiveness of therapies in clinical studies and
real-world practice [11]. The Psoriasis Area and
Severity Index (PASI) is a commonly used
instrument for measuring psoriasis severity and
evaluating treatment response. PASI scores
measure psoriasis symptom involvement of four
body sections: head, upper extremities, trunk,
and lower extremities [12]. The static Physician
Global Assessment (sPGA) is a widely used,
clinician-reported instrument for measuring
psoriasis severity based on induration, scaling,
and erythema, with scores from 0 (clear) to 5
(severe) [13]. Although clinician-reported
instruments can provide objective assessments
of symptom control, assessments of treatment
effectiveness must also include the patient per-
spective, particularly during clinical trials used
to inform treatment selection and optimization
in real-world practice. This requires the use of
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instruments that incorporate patient-reported
outcomes (PROs) [14, 15]. The Dermatology
Quality Index (DLQI) is a PRO tool used to
assess HRQL across six domains (patient’s per-
ception of symptoms and feelings, daily activi-
ties, leisure, work and school, interpersonal
relationships, and treatment) [16].
Risankizumab is a fully humanized mono-
clonal antibody with a high affinity for the p19
component of interleukin (IL)-23, a cytokine
that plays a key role in the pathogenesis of
psoriasis [17]. Recently, data from four large,
multicenter, phase 3 randomized controlled
trials, including UltIMMa-1 (NCT02684370),
UltIMMa-2 (NCT02684357), IMMvent
(NCT02694523), and IMMhance
(NCT02672852), showed significantly greater
efficacy with risankizumab versus placebo
[18–20], ustekinumab [19], and adalimumab
[20] as measured by relative improvements from
baseline in PASI and DLQI. The IMMhance trial
also investigated the impact of randomized
withdrawal from risankizumab among patients
who achieved an initial response at week 28
[18]. Data from IMMhance showed that con-
tinuous treatment provided significantly better
long-term disease control than withdrawal (at
week 52: 87% versus 61%, p\ 0.001) [21].
However, in IMMhance, DLQI was only col-
lected through week 16, and thus the corre-
sponding impact of treatment withdrawal on
HRQL could not be directly assessed. To cir-
cumvent the limitation of outcome availability
only for a limited number of patient visits, the
current study assessed the deterioration of
HRQL following risankizumab treatment with-
drawal using a machine learning predictive




The data used in this study were from four
phase-3 randomized, double-blind controlled,
trials (UltIMMa-1, UltIMMa-2, IMMvent, and
IMMhance) of risankizumab for the treatment
of moderate-to-severe plaque psoriasis (Fig. 1).
UltIMMa-1 and UltIMMa-2 Trials
Patients in the UltIMMa-1 and UltIMMa-2 trials
were randomized 3:1:1 at baseline to risankizu-
mab (150 mg at weeks 0 and 4 followed by every
12 weeks), ustekinumab (45 or 90 mg at weeks 0
and 4 followed by every 12 weeks), or placebo
(weeks 0 and 4 followed by cross-over to risan-
kizumab 150 mg every 12 weeks after an initial
16-week double-blind period)[19]. DLQI was
collected at weeks 0, 12, 16, and 52. Candidate
predictor variables were collected at all visits
through week 52.
IMMvent Trial
Patients in the IMMvent trial were randomized
1:1 at baseline to risankizumab (150 mg at
weeks 0 and 4 followed by every 12 weeks) or
adalimumab (90 mg at week 0, followed by
40 mg at week 1 and every 2 weeks there-
after)[20]. At week 16, patients initially ran-
domized to adalimumab were switched to
risankizumab if\PASI50, remained on adali-
mumab if C PASI90, or were re-randomized 1:1
to either risankizumab or adalimumab if C
PASI50 and\PASI90. DLQI was collected at
weeks 0, 16, and 44. Candidate predictor vari-
ables were collected at all visits through week
44.
IMMhance Trial
Patients in the IMMhance trial were random-
ized 4:1 at baseline to risankizumab 150 mg or
placebo [18]. Patients received a dose of study
medication at week 0, week 4, and every
12 weeks thereafter. At week 16, patients ran-
domized to placebo started receiving active
treatment with risankizumab 150 mg every
12 weeks and continued until the end of the
treatment period. At week 28, patients ran-
domized to risankizumab who achieved an
sPGA score of 0 or 1 were re-randomized to
either risankizumab or placebo. Starting from
week 32, week 28 responders who experienced
relapse (sPGA C 3) were switched to open-label
risankizumab 150 mg every 12 weeks. DLQI was
collected at weeks 0, 12, and 16. Candidate
predictor variables were collected at all visits
through week 104.
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Inclusion Criteria
Model development included all patients in the
intention-to-treat populations of UltIMMa-1,
UltIMMa-2, and IMMvent who had visits with
concurrently available DLQI and predictor
variable measurements. External model valida-
tion included all patients in the intention-to-
treat population of the IMMhance trial who had
visits with concurrently available DLQI and
predictor variable measurements at weeks 0, 12,
or 16. In the score prediction phase, DLQI
scores were predicted among patients originally
randomized to risankizumab in IMMhance who
achieved sPGA of 0 or 1 at week 28 and were
consequently re-randomized to continue risan-
kizumab or switch to placebo. The treatment
cohort was defined according to the intention-
to-treat re-randomization group. DLQI scores
were predicted for patient visits with concur-
rently available predictor variable
measurements.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not contain any new studies
with human participants performed by any of
the authors. The trials included in this study
were approved by each site’s institutional
review board and were performed in accordance
with the Helsinki Declaration of 1964, and its
later amendments.
Outcome Measure and Candidate
Predictors
The outcome of interest was the total DLQI
score, which served as the dependent variable in
the predictive regression models.
Candidate predictors including the PASI
total score, PASI body section subscores, and the
sPGA score were considered for inclusion in the
prediction model of DLQI as concurrent mea-
sures of psoriasis severity. Baseline candidate
predictors included demographics (age, sex, and
race), weight, duration of psoriasis, and history
of use of systemic biologic therapy. Addition-
ally, several squared terms (age2, weight2, dis-
ease duration2, sPGA2, total PASI2) and
interaction terms (PASI 9 age, PASI 9 weight,
PASI 9 sex, sPGA 9 age, sPGA 9 weight,
sPGA 9 sex) were considered as candidate
predictors.
Fig. 1 Data sources and patient flowchart in the clinical
trials included in the analysis. At week 28 of IMMhance,
patients originally randomized to risankizumab who
achieved a sPGA score of 0 or 1 were re-randomized to
either risankizumab or placebo. Starting from week 32,
week 28 responders who experienced relapse (sPGA C 3)
were switched to open-label risankizumab 150 mg. ADA
adalimumab, Q2W every 2 weeks, Q12W every 12 weeks,
RZB risankizumab, UST ustekinumab, Wk week
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Baseline Characteristics
Baseline characteristics were summarized for
the intention-to-treat populations in UltIMMa-
1, UltIMMa-2, IMMvent, and IMMhance, and
for each re-randomized cohort in IMMhance.
Patient characteristics assessed included DLQI
and all candidate predictors. Means and stan-
dard deviations were summarized for continu-
ous variables; counts and percentages were
summarized for categorical variables. Statistical
comparisons between re-randomized cohorts in
the IMMhance trial were conducted using one-
way analysis of variance for continuous vari-
ables and v2 tests for dichotomous variables.
Model Development and Validation
Repeated-measures linear regression models for
DLQI score prediction were developed with
pooled data from UltIMMa-1, UltIMMa-2, and
IMMvent, using cross-validation to prevent
model overfitting. In addition to several model
specifications with progressively expanded pre-
dictor subsets, machine learning algorithms
including elastic net and least absolute shrink-
age and selection operator (LASSO) regression
were used to automate variable selection from
among the full set of candidate predictors. The
best-fitting models were further validated in the
IMMhance population using all patient visits
with concurrently available DLQI scores (at
weeks 0, 12, and 16) and predictor variables.
The predictive performance of all models was
assessed using the cross-validated mean abso-
lute error (MAE) and the coefficient of deter-
mination (R2).
DLQI Prediction and Calculation of DLQI
and PASI Deterioration
Longitudinal analyses of predicted DLQI scores
were conducted to examine the deterioration of
HRQL associated with risankizumab treatment
withdrawal after achievement of response in the
IMMhance trial. The treatment cohort [risanki-
zumab versus placebo, (i.e., withdrawal)] was
defined according to intention-to-treat re-ran-
domization groups. For each study visit in part
B (weeks 28 ?) of the IMMhance trial, the mean
change in DLQI score from baseline was mod-
eled in each re-randomization group based on
the difference between DLQI scores predicted at
the visit versus the score observed at baseline. A
bootstrapping approach was used to obtain 95%
confidence intervals (CIs) around the mean
change from baseline in DLQI in each re-ran-
domization group and around the between-
group difference at each visit. Percent mainte-
nance of score improvement from baseline to
week 28 was assessed for predicted DLQI scores
and observed PASI in each re-randomization
group. For patients who switched to open-label
risankizumab because of relapse, or who were
lost to follow-up, last observation carried for-
ward (LOCF) was used to impute PASI and sPGA
scores at subsequent visits. Additional method-
ological details are provided in Appendix 1 of
the electronic supplementary material.
RESULTS
Baseline Characteristics
A total of 2109 subjects were included in the
samples used for model training and validation
(UltIMMa-1 and UltIMMa-2: 997; IMMvent:
605; IMMhance: 507), and 336 subjects were
included in the sample used for DLQI predic-
tion (IMMhance re-randomized placebo: 225;
risankizumab: 111). Baseline characteristics
were well balanced across the intention-to-treat
populations of the clinical trials used in the
model development and validation phase
(Table 1). The mean age across cohorts ranged
between 46.2 and 49.3 years, and between
25.2% and 30.7% of patients were female. The
mean DLQI score ranged between 13.0 and
13.7, and the total PASI score ranged between
19.7 and 20.2. Similarly, baseline characteristics
were balanced across the re-randomized cohorts
used for longitudinal DLQI score predictions.
Model Development and Validation
The prediction models for DLQI demonstrated
significant, positive associations between DLQI
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and PASI across all specifications tested (Sup-
plemental Table S1). The saturated model and
elastic-net selected model demonstrated the
best predictive performance out of the models
tested, as measured by R2 and MAE. Due to the
high predictive performance and relative parsi-
mony, the elastic net model was chosen for the
prediction of longitudinal DLQI scores among
re-randomized patients in part B of the
IMMhance trial.
The predicted DLQI scores among patients
who were re-randomized at week 28 in the
IMMhance trial mirrored the observed DLQI
scores closely at weeks 0, 12, and 16, further
demonstrating the high out-of-sample predic-
tive performance of the elastic net model
(Fig. 2a). Moreover, the predicted DLQI scores
closely mirrored the observed scores for patients
in the UltIMMa-1/2 and IMMvent trials who
achieved PASI100 response at week 16 but then
lost this response at week 52 or 44 (Fig. 2b),
confirming the high predictive performance of
the elastic net model among patients who
Table 1 Baseline characteristics for patients whose data were used in the study











N = 997 N = 605 N = 507 N = 225 N = 111
Demographics and clinical characteristics
Age (years), mean (SD) 47.4 ± 13.7 46.2 ± 13.5 49.2 ± 13.3 49.3 ± 13.1 48.2 ± 13.4 0.457
Female, n (%) 300 (30.1%) 183 (30.2%) 151 (29.8%) 69 (30.7%) 28 (25.2%) 0.301
White race, n (%) 778 (78.0%) 508 (84.0%) 402 (79.3%) 177 (78.7%) 82 (73.9%) 0.326
Weight (kg), mean (SD) 90.1 ± 21.9 90.1 ± 23.9 92.0 ± 22.9 91.0 ± 22.2 91.3 ± 23.7 0.897
Duration of psoriasis (years),
mean (SD)
18.1 ± 12.5 18.2 ± 12.3 19.9 ± 13.0 20.4 ± 13.4 19.4 ± 13.1 0.505
Prior biologic systemic therapy,
n (%)
377 (37.8%) 229 (37.9%) 281 (55.4%) 125 (55.6%) 57 (51.4%) 0.467
Measure of disease severity, mean (SD)
DLQI 13.0 ± 7.0 13.7 ± 7.2 13.4 ± 7.1 13.0 ± 7.2 13.0 ± 6.9 0.992
sPGA 3.2 ± 0.4 3.2 ± 0.4 3.2 ± 0.4 3.2 ± 0.4 3.2 ± 0.4 0.302
PASI score
Total PASI score 20.1 ± 7.4 19.8 ± 7.5 20.2 ± 8.1 19.7 ± 7.3 20.2 ± 8.9 0.526
Subtotal (area score 9 lesion score)
Head 16.3 ± 11.9 16.9 ± 11.8 17.0 ± 11.2 16.7 ± 10.3 18.8 ± 13.1 0.113
Trunk 18.1 ± 10.3 17.9 ± 9.8 18.5 ± 10.7 18.2 ± 9.5 18.5 ± 11.8 0.759
Upper extremities 19.5 ± 9.1 18.5 ± 9.1 19.4 ± 9.1 19.3 ± 9.0 18.9 ± 9.0 0.724
Lower extremities 22.9 ± 9.7 22.7 ± 10.1 22.6 ± 10.5 21.7 ± 9.7 22.6 ± 11.4 0.485
DLQI Dermatology Life Quality Index, PASI Psoriasis Area and Severity Index, PBO placebo, RZB risankizumab, SD
standard deviation, sPGA static Physician’s Global Assessment
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respond to therapy and then experience a
deterioration of response.
Predicted Change in DLQI
Analysis of predicted DLQI scores using the
elastic net model revealed significantly greater
deterioration in the cohort re-randomized to
placebo relative to the cohort re-randomized to
continue risankizumab treatment (Fig. 3a).
There was a statistically significant difference in
the change in DLQI from baseline between
cohorts at week 52 [difference-in-differ-
ence = 1.7; 95% CI = (0.2, 3.4)]. Beyond week
52, increasingly larger mean changes in DLQI
scores were observed in the withdrawal cohort
relative to the risankizumab cohort. These dif-
ferences were significant at each visit beyond
week 52. Raw predicted DLQI scores among re-
randomized patients are shown in Supplemen-
tal Fig. S1.
Fig. 2 a Mean predicted versus observed DLQI scores for
weeks 0–16 among patients re-randomized at week 28 in
the IMMhance trial; b mean predicted versus observed
DLQI scores in the UltIMMa-1, UltIMMa-2, and
IMMvent trials among patients who achieved PASI 100
response at week 16 and then lost PASI 100 response at
week 44 or 52. DLQI Dermatology Life Quality Index,
PASI Psoriasis Area and Severity Index
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Maintenance of DLQI and PASI Score
Improvement
The cohort re-randomized to placebo showed
deterioration in observed PASI scores and pre-
dicted DLQI scores over time, while the cohort
re-randomized to continue risankizumab treat-
ment had near-complete maintenance of both
scores (Fig. 3). Predicted improvements in DLQI
from baseline were lower in the withdrawal
versus the continuation cohort [mean DLQI
change at week 104, -5.9 versus -11.5, differ-
ence, 95% CI = 5.6 (4.1, 7.3)] (Fig. 3a). For
patients in the withdrawal cohort, the DLQI
score improvement achieved from baseline to
week 28 deteriorated more rapidly after with-
drawal compared with the deterioration in PASI
score improvement (Fig. 4). At the end of fol-
low-up (week 104), DLQI score improvement
from baseline to week 28 had deteriorated by
49.7%; PASI score improvement at week 28
deteriorated by 36.4% by week 104. The
Fig. 3 a Change in predicted DLQI from baseline among
re-randomized patients in the IMMhance trial. DLQI
scores were predicted among patients originally random-
ized to risankizumab who were consequently re-random-
ized to continue risankizumab or switch to placebo in part
B (weeks 28 ?) of the IMMhance trial. An LOCF
method was used to carry forward measurements for visits
with missing measures; b change in PASI from baseline
among re-randomized patients in the IMMhance trial.
PASI scores were assessed among patients originally
randomized to risankizumab who were consequently re-
randomized to continue risankizumab or switch to placebo
in part B (weeks 28 ?) of the IMMhance trial. An LOCF
method was used to carry forward measurements for visits
with missing measures. CI confidence interval, DLQI
Dermatology Life Quality Index, LOCF last observation
carried forward, PBO placebo, RZB risankizumab
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difference in deterioration of DLQI versus PASI
among patients who withdrew from risankizu-
mab was statistically significantly different by
week 40 [difference (95% CI) = -1.6% (-2.9%,
-0.2%)], and in all weeks thereafter (Fig. 4).
Changes in sPGA from baseline are shown in
Supplemental Figure S2.
DISCUSSION
Achieving skin clearance is a meaningful
improvement to patients with moderate-to-
severe psoriasis [22]. Due to the chronic nature
of the disease, patients with psoriasis require
ongoing treatment to adequately manage
symptoms [23]. Although guidelines recom-
mend continuous therapy for patients with
psoriasis who are treated with biologic agents
[24, 25], gaps in treatment are common in
clinical practice [26, 27]. Reasons for treatment
interruption vary but can include lack of
meaningful improvement, adverse events, and/
or patient preference to avoid continuous
treatment [28, 29]. The present study demon-
strated that the predicted HRQL worsened at a
higher rate compared with the PASI score fol-
lowing treatment discontinuation. Despite the
significant durability of patients’ response to
risankizumab following withdrawal, the deteri-
oration of HRQL is more rapid. These findings
align with previous studies, which show that,
regardless of the reason for treatment gaps,
treatment discontinuation negatively affects
patients’ HRQL, particularly those responsive to
therapy. Results from a post hoc subanalysis of
the double-blind, phase 3 REVEAL trial reported
a twofold greater deterioration of HRQL mea-
sured by DLQI compared with PASI following
withdrawal of adalimumab [30]. Although the
results do not allow the identification of the
cause for the disproportionate worsening of
DLQI, previous research suggests that psycho-
logical impacts of disease worsening may be
responsible for this pattern [30, 31]. Given the
importance in identifying the impact of chan-
ges in HRQL to guide treatment optimization,
additional studies are warranted to further
assess the impact of treatment withdrawal
among patients with psoriasis.
Methodologically, this study used several
regression and machine learning model
Fig. 4 Maintenance of DLQI and PASI score improve-
ment following treatment re-randomization in the
IMMhance trial. Maintenance of score improvement from
week 28 was calculated as 100%—[100% 9 (change in
score from baseline to week 28 - change in score from
baseline to week x)/(change in score from baseline to week
28)]. Maintenance of 100% indicates complete mainte-
nance of week 28 improvement; maintenance of 0%
indicates a return to baseline score. The vertical line at
week 40 indicates the first visit when the percent
deterioration difference in DLQI versus PASI becomes
statistically significant. DLQI Dermatology Life Quality
Index, LOCF last observation carried forward, PASI
Psoriasis Area and Severity Score, PBO placebo, RZB
risankizumab
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specifications based on patient characteristics
(e.g., age, disease duration, treatment history)
and well-established measures of disease sever-
ity to achieve robust performance in predicting
DLQI scores and thus overcome the challenge of
unmeasured scores. The cross-validation proce-
dure helped protect against overfitting, while
the additional model testing with IMMhance
data at weeks 0, 12, and 16 indicated high out-
of-sample predictive ability. Results of the pre-
sent study showed that the elastic net model
achieved the best trade-off between predictive
accuracy and model parsimony, highlighting
the value of machine learning approaches in
selecting relevant predictors among multiple
highly correlated measures.
Overall, the findings from the machine
learning procedure align with results from prior
studies that analyzed determinants of HRQL as
assessed using DLQI [32–38]. Several studies to
date have reported a strong relationship
between PASI and DLQI, in diverse patient
populations and various settings worldwide
[32–38]. Moreover, this is the first study to
develop a model for out-of-sample prediction of
DLQI based on a diverse set of patient and dis-
ease characteristics in psoriasis, and explains a
higher proportion of the variation than a pre-
vious multivariate model [33]. Based on the
models presented, sPGA was predictive of DLQI
independently of PASI. This is consistent with
previous research showing that, although sPGA
and PASI correlate well, the correlation is
weaker at the ends of the distribution, which
indicates that the two measures may provide
independent information about disease severity
[39]. The residual predictive ability of the head
subscore of PASI was also consistent with a prior
study that demonstrated that patients with
psoriasis with visible psoriatic lesions have sig-
nificantly worse HRQL compared with those
with nonvisible lesions [33].
Finally, the preferred model specification
suggests that the relationship between PASI and
DLQI is nonlinear, as indicated by the selection
of the PASI squared terms as statistically signif-
icant predictors of DLQI scores in addition to
the linear PASI total score term. This is consis-
tent with a previous analysis of the relationship
between disease severity as measured by PASI
and HRQL as measured by EQ-5D-3L [40],
which also found a nonlinear association
between the two measures. In that analysis,
increases in PASI close to zero were shown to
have a larger impact on EQ-5D-3L compared
with an equally sized increase in PASI at the
higher end of the scale, as determined by the
inclusion of a PASI squared term as a significant
predictor of EQ-5D-3L.
Limitations
This study has several limitations. First, as with
all trial-based analyses, the results may not be
generalizable to a real-world population, as the
study population comprised a group of patients
selected on the basis of specific enrollment cri-
teria and followed under well-controlled con-
ditions. Second, despite the high predictive
performance of the selected model, the exclu-
sion of other variables not measured in the trial
or unavailable at all time points may contribute
to prediction error at the individual patient
level. The model closely predicted aggregate-
level average DLQI scores during external vali-
dation, but does not fully explain heterogeneity
in DLQI scores across different patients. Third,
this study assumed that achieving a given level
of clinical symptom control (as measured by
PASI and sPGA scores) has the same HRQL
benefits regardless of the specific treatment
strategy that resulted in that symptom control.
However, patients may experience different
types and rates of adverse events depending on
treatment, which could also contribute to
heterogeneity in the HRQL benefits of different
treatment strategies. Lastly, inherent limita-
tions exist for the assessments of interest. For
example, limitations with the DLQI include
inadequate measurement of mild illness and
differential item functioning by disease, age,
and sex [41, 42], whereas limitations of PASI
include poor sensitivity, nonlinear scale, lack of
correspondence to clinical severity categories
[43], and dependence on the experience level of
the clinician performing the measurement [44].
Moreover, lower PASI values are less clinically
meaningful, thus precluding valid comparisons
across the entire spectrum of PASI scores [30].
1300 Dermatol Ther (Heidelb) (2021) 11:1291–1304
CONCLUSIONS
Predicted DLQI scores revealed an association
between risankizumab treatment withdrawal
and HRQL deterioration, as evidenced by a
progressive increase in the mean change in the
predicted DLQI scores among patients who
discontinued versus those who remained on
treatment. The predicted HRQL deteriorated
more rapidly than the PASI score, an objective
measure of disease.
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O, Gulácsi L. Health status and quality of life in
Dermatol Ther (Heidelb) (2021) 11:1291–1304 1303
patients with psoriasis: an Iranian cross-sectional
survey. Arch Iran Med. 2015;18(3):1.
37. Mabuchi T, Yamaoka H, Kojima T, Ikoma N, Aka-
saka E, Ozawa A. Psoriasis affects patient’s quality of
life more seriously in female than in male in Japan.
Tokai J Exp Clin Med. 2012;37(3):84–8.
38. Tsai T-F, Ho J-C, Chen Y-J, Hsiao P-F, Lee W-R, Chi
C-C, et al. Health-related quality of life among
patients with moderate-to-severe plaque psoriasis in
Taiwan. Dermatol Sin. 2018;36(4):190–5.
39. Robinson A, Kardos M, Kimball AB. Physician Glo-
bal Assessment (PGA) and Psoriasis Area and
Severity Index (PASI): why do both? A systematic
analysis of randomized controlled trials of biologic
agents for moderate to severe plaque psoriasis. J Am
Acad Dermatol. 2012;66(3):369–75.
40. Geale K, Henriksson M, Schmitt-Egenolf M. How is
disease severity associated with quality of life in
psoriasis patients? Evidence from a longitudinal
population-based study in Sweden. Health Qual
Life Outcomes. 2017;15(1):151.
41. Bronsard V, Paul C, Prey S, Puzenat E, Gourraud PA,
Aractingi S, et al. What are the best outcome mea-
sures for assessing quality of life in plaque type
psoriasis? A systematic review of the literature. J Eur
Acad Dermatol Venereol. 2010;24:17–22.
42. Twiss J, Meads DM, Preston EP, Crawford SR,
McKenna SP. Can we rely on the Dermatology Life
Quality Index as a measure of the impact of psori-
asis or atopic dermatitis? J Invest Dermatol.
2012;132(1):76–84.
43. Berth-Jones J, Grotzinger K, Rainville C, Pham B,
Huang J, Daly S, et al. A study examining inter- and
intrarater reliability of three scales for measuring
severity of psoriasis: Psoriasis Area and Severity
Index, Physician’s Global Assessment and Lattice
System Physician’s Global Assessment. Br J Derma-
tol. 2006;155(4):707–13.
44. Langley RG, Ellis CN. Evaluating psoriasis with
Psoriasis Area and Severity Index, Psoriasis Global
Assessment, and Lattice System Physician’s Global
Assessment. J Am Acad Dermatol. 2004;51(4):
563–9.
1304 Dermatol Ther (Heidelb) (2021) 11:1291–1304
